CLB vs ENB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLB exhibits a concerning divergence between its current market price ($17.45) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health. The stock is trading at a significant premium to both its Graham Number ($9.04) and Intrinsic Value ($4.41), while experiencing a sharp YoY earnings decline of 31.60%. Despite a strong 1-year price rally, the underlying fundamentals—specifically the negative earnings growth and bearish technical trend—suggest the current valuation is unsustainable.
Enbridge presents a conflicted profile with a stable Piotroski F-Score of 4/9, but significant valuation and sustainability concerns. While the intrinsic value estimate is high ($69.62), the Graham Number ($31.45) suggests the stock is trading at a steep premium to its defensive value. The most critical red flag is a payout ratio of 117.08%, indicating that dividends are currently funded by debt or cash reserves rather than earnings. Combined with a bearish technical trend (10/100) and a current price exceeding the analyst target of $51.13, the outlook is cautious.
Compare Another Pair
Related Comparisons
CLB vs ENB: Head-to-Head Comparison
This page compares Core Laboratories Inc. (CLB) and Enbridge Inc. (ENB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.